NT-proBNP is initially produced as a part of a larger precursor molecule called proBNP. This proBNP is then cleaved into two biologically active peptides: BNP (B-type Natriuretic Peptide) and NT-proBNP. While BNP has a relatively short half-life and is cleared from circulation quickly, NT-proBNP remains in the bloodstream for a longer period, making it a more reliable biomarker for the diagnosis and management of heart failure and other cardiovascular diseases. It is also has been employed in the risk stratification of patients with acute coronary syndromes and heart failure. Elevated levels are associated with an increased risk of mortality and adverse outcomes in these patient populations.
On April 2023, Hipro's NT-proBNP test kit finished the clinical trial experiment in Western China Hospital. We compare the test results analysed by our Fluorescence Immunoassay Analyer and the test results are highly correlated with Roche electrochemiluminescence analyzer. The clinical trial report shows that the serum sample data slightly better than whole blood sample data and the serum and whole blood test are highly correlated with Roche data so oth t5he serum test and whold blood test are suitable for clinical diagnosis.
